{"id":"W2533374120","doi":"10.1017/cjn.2016.382","title":"PC3 - 155 Phase II Study of Dianhydrogalactitol in Patients with MGMT-Unmethylated, Bevacizumab-Naïve Recurrent Glioblastoma","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Bevacizumab; Lomustine; Temozolomide; Medicine; Oncology; Internal medicine; Clinical trial; Phases of clinical research; Biomarker; Chemotherapy; Vincristine; Cyclophosphamide; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00128372,0.001900224,0.00195091,0.0004916211,0.0003749679,0.001185032,0.00121336,0.001429802,0.005308342],"category_scores_gemma":[0.0007787384,0.000556872,0.001294041,0.0005126089,0.001039264,0.000808513,0.0003780529,0.003352464,0.001391501],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001653112,"about_ca_system_score_gemma":0.003173079,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003992451,"about_ca_topic_score_gemma":0.01065974,"domain_scores_codex":[0.9996405,0.0001383734,0.00002049602,0.00006934733,0.00004259148,0.00008882026],"domain_scores_gemma":[0.9995418,0.00003783101,0.00007348022,0.00003894575,0.00004385884,0.0002641105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.782823,0.07207462,0.002662028,0.001433217,0.00165845,0.0002224549,0.0002469199,0.001884639,0.04194263,0.0004893509,0.008885134,0.08567744],"study_design_scores_gemma":[0.6656418,0.3219502,0.005038971,0.00005401481,0.0004037285,0.0001296399,0.00004977653,0.0007872945,0.002730269,0.0002877392,0.002894935,0.00003159719],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822693,0.003485668,0.0008114741,0.0009629718,0.0003413901,0.006031304,0.002276545,0.0002976786,0.003523795],"genre_scores_gemma":[0.9759759,0.003192434,0.002255428,0.002484301,0.0002321928,0.005395723,0.004691956,0.00006922869,0.005702795],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005308342,"threshold_uncertainty_score":0.01775813,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02194092493091893,"score_gpt":0.2797746631681409,"score_spread":0.257833738237222,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}